<h1 id="neutropenic-fever-and-cancer">Neutropenic Fever and Cancer</h1>
<p>Chemotherapy causes neutropenia in 10-50% of patients with solid tumors and &gt; 80% of patients with hematologic malignancies during chemotherapy cycle</p>
<p><strong>Fever:</strong> ≥ 38.3 C (101 F) or ≥ 38.0 C (100.4 F) over 1-hour period</p>
<p><strong>Neutropenia:</strong> Absolute neutrophil count &lt; 500 cells/mm3</p>
<h2 id="mascc-score">MASCC score</h2>
<p><strong>Multinational Association for Supportive Care in Cancer (MASCC) Score:</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Burden of febrile neutropenia</strong></td>
<td>5 pts (mild), 3 pts (moderate)</td>
</tr>
<tr>
<td><strong>No hypotension (SBP ≥ 90 mmHg)</strong></td>
<td>5 pts</td>
</tr>
<tr>
<td><strong>No COPD</strong></td>
<td>4 pts</td>
</tr>
<tr>
<td><strong>Solid tumor or hematologic malignancy <span class="drug">with</span> no previous fungal infection</strong></td>
<td>4 pts</td>
</tr>
<tr>
<td><strong>No dehydration requiring parenteral fluids</strong></td>
<td>3 pts</td>
</tr>
<tr>
<td><strong>Outpatient status</strong></td>
<td>3 pts</td>
</tr>
<tr>
<td><strong>Age &lt; 60 years</strong></td>
<td>2 pts</td>
</tr>
</tbody>
</table>
<p><strong>HIGH RISK PATIENTS</strong> (require admission):</p>
<ul>
<li>MASCC score &lt; 21 <strong>OR</strong></li>
<li>Any of clinical findings:<ul>
<li>Prolonged (&gt; 7 days duration) and profound neutropenia (ANC ≤ 100 cells/mm3)</li>
<li>Hypotension</li>
<li>Pneumonia</li>
<li>New abdominal pain</li>
<li>Neurologic changes</li>
</ul>
</li>
</ul>
<p><strong>LOW RISK PATIENTS</strong> (may be eligible for outpatient tx):</p>
<ul>
<li>MASCC score ≥ 21</li>
<li>Brief (≤ 7 days duration) neutropenic periods and few co-morbidities</li>
</ul>
<h2 id="workup">Workup</h2>
<ul>
<li>CBC, BUN/Creatinine, electrolytes, AST/ALT, bilirubin</li>
<li>Chest xray, if respiratory signs or symptoms</li>
<li>2 Blood Cx (1 central line lumen if present + 1 peripheral vein, or 2 peripheral veins)</li>
</ul>
<h2 id="antibiotic-treatment">Antibiotic Treatment</h2>
<p><em>Monotherapy:</em> Antipseudomonal beta-lactam (eg. <strong><span class="drug">cefipime</span>, <span class="drug">carbapenem</span>, <span class="drug">pip-tazo</span></strong>)
<strong><span class="drug">Vancomycin</span></strong>is not always indicated in cancer patients with a neutropenic fever.</p>
<ul>
<li>Add <strong>vancomycin</strong> only if suspect catheter-related infection, skin/soft tissue infection, pneumonia, hemodynamic instability, colonization with MRSA/VRE/PCN-resistant <em>Strep pneumoniae</em></li>
</ul>
<p><em>For PCN allergy</em>: <strong><span class="drug">Ciprofloxacin</span> + <span class="drug">clindamycin</span>,</strong> or <strong><span class="drug">aztremonam</span> + <span class="drug">vancomycin</span></strong>
<em>For PO outpatient</em>: <strong><span class="drug">Ciprofloxacin</span> + <span class="drug">amoxicillin-clavulanate</span> </strong></p>
<h2 id="central-line-associated-blood-stream-infection-clabsi-">Central line-associated blood stream infection (CLABSI)</h2>
<p><strong>Remove catheter:</strong> Consider removal if any of following: </p>
<ul>
<li>Caused by <em>S. aureus</em>, <em>P. aeruginosa</em>, fungi, mycobacteria</li>
<li>Tunnel infection</li>
<li>Pocket site infection</li>
<li>Septic thrombosis</li>
<li>Endocarditis</li>
<li>Sepsis with hemodynamic instability</li>
<li>Bacteremia despite ≥ 72 hours antibiotics</li>
</ul>
<p><strong>Keep catheter</strong> and treat with abx: If coag-negative staph</p>
<h2 id="example">Example</h2>
<p>A 65 y/o man with a history of prostate cancer presents to your ED from home appearing fairly well and a mild cough for 3 days. He has otherwise no past medical problems. His vital signs are:</p>
<ul>
<li>Temperature 39 C</li>
<li>BP 160/80</li>
<li>HR 60</li>
<li>RR 14</li>
<li>Oxygen saturation 99% on room air</li>
</ul>
<p>His absolute neutrophil count (ANC) comes back at 300 cells/mm3. His chest xray shows a right middle lobe pneumonia and a central line catheter tip ending in the SVC.</p>
<p><strong>Questions:</strong></p>
<ul>
<li>Is this a patient &quot;high&quot; or &quot;low&quot; risk per the Multinational Association for Supportive Care in Cancer (MASCC)? (<span class="aglmd-moreinfo ui-moreinfo" data-iid="53aa2472d35d3ae92e001575">View answer</span>)</li>
<li>Does this person require inpatient admission? (<span class="aglmd-moreinfo ui-moreinfo" data-iid="53aa2472d35d3ae92e001576">View answer</span>)</li>
<li>What antibiotics would you start on this patient? (<span class="aglmd-moreinfo ui-moreinfo" data-iid="53aa2472d35d3ae92e001577">View answer</span>)</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/21205990">Fairefield AG et. al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. 2010 update by the IDSA. Clinical Infectious Disease 2011; 52 (4): e56-93.</a></li>
</ul>
